礼来公司周五表示，欧洲药品管理局人用药品委员会（Committee for Medicinal Products for Human Use）已建议扩大其癌症药物吡托布鲁替尼（Jaypirca）在某些慢性淋巴细胞白血病患者中的批准范围。

　　礼来表示，该建议涵盖Jaypirca用于治疗既往接受过布鲁顿酪氨酸激酶抑制剂治疗的复发，或难治性慢性淋巴细胞白血病成人患者。

　　这家制药商表示，通常遵循欧洲药品管理局人用药品委员会建议的欧盟委员会预计将在未来一到两个月内做出最终决定。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：张俊 SF065

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.